67 WALL STREET, New York - March 25, 2014 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Affordable Care Act - Aging U.S. Population - End Market Improvement - Biotech, Pharma and Medical Device Convergence - Changing Competitive Dynamics
Companies include: Cyberonics Inc. (CYBX), Celgene Corporation (CELG), Vision-Sciences Inc. (VSCI), Cytori Therapeutics, Inc. (CYTX) and many others.
In the following excerpt from the Medical Devices Report, an award winning analyst discusses the outlook for the sector for investors:
TWST: You garner a lot of attention for your biotech coverage. How does medical devices fit in there, and how do you break down devices versus biotech?
Mr. Brozak: I've also focused on the device side. In 2011, I was The Wall Street Journal's top Analyst in research recommendation performance for medical devices. All of the sectors of health care are now joined at the hip, so we have a real focus in all areas and how they relate to each other. Take Navidea (NAVB), it's a perfect example. In complete disclosure, we do own warrants in the company for having advised them and done banking for them.
This is a small-cap company that we believe is a significant player in the future of all cancer therapies. When we started coverage of them and working with them, they were selling a medical device, which, by detecting the radioactive isotope technetium-99, gave physicians the ability to go into the lymphatic system and stage patients correctly with, at the time, breast cancer and melanoma. On the biotech side, they needed a better and, frankly, FDA-approved contrast agent, which they developed and called Lymphoseek. It was better, smaller and now reimbursed.
The company has since sold off their detection device systems. They're still employed, and they're still state-of-the-art, because they improved them. And now they've introduced a biotech type of contrast agent that's much smaller, much more sensitive and less painful, because they fine-tuned it to an individual's pH. The old stuff used was very, very acidic, and as a result it burned the patients. This is a convergence now. You've got a far superior biotech product for the detection of solid tumors. It is specifically tied to a device, a little wand, which maps the lymph nodes and helps to monitor the progression of solid tumors. The FDA even stated that it was most important approval that they've seen in 30 years in oncology.
Navidea just filed for a new indication, head and neck, areas of the body that you've never been able to do in this space. I believe you can apply this for lung, prostate and every other solid tumor in the body. Now, what is that going to do in terms of staging for future solid tumor patients? Obviously if you can catch, say, lung cancer while it's still in the lungs and be confident that it hasn't metastasized, that's terribly important.
TWST: You have been following them a long time?
Mr. Brozak: Seven years. Another company that we've been following for just as long is...
For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.